Back

GLP-1 Analogues and cardiovascular risk reduction in adults with obesity and elevated CRP: a real-world matched cohort study

29 August 2026 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Improving understanding in cardiomyopathies and myocardial disease Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Susan Keen

Cleveland Clinic, Cleveland (United States of America)

5 More presentations in this session

Presentation thumbnail
AI-enabled electrocardiography as a screening tool for peripartum cardiomyopathy: a meta-analysis of diagnostic accuracy
Doctor G. Caldeira Gaelzer (Curitiba, BR)
Abstract
Presentation thumbnail
Left bundle branch block in gene-elusive dilated cardiomyopathy is associated with better prognosis
Doctor D. Cannie (London, GB)
Abstract
Presentation thumbnail
Desmoglein-2 splice-site variant associated with arrhythmogenic right ventricular cardiomyopathy: description of ten patients and hypothesis of a founder effect
Doctor M. Proust (Paris, FR)
Abstract
Presentation thumbnail
Overlapping phenotype of arrhythmogenic cardiomyopathy and left ventricular hypertrabeculation: clinical characteristics and prognostic implications
Mr L. Qi (Beijing, CN)
Abstract
Presentation thumbnail
Interpretable machine learning for detecting coronary heart disease comorbidity in hypertension: key roles of cardiometabolic indices
Mr X. Ma (Lanzhou, CN)
Abstract

Access the full session

Session thumbnail
Improving understanding in cardiomyopathies and myocardial disease

The Event

Event poster

ESC Congress 2026

29 August 2026 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of GLP-1 agonists in obesity-related heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized placebo-controlled trials.
1 September 2025
thumbnail
Congress Presentation
The real-life prevalence and risk factors of elevated CRP in patients from cardiology outpatient clinics. The results from the STAR-Lp(a) study.
1 September 2025
thumbnail
Congress Presentation
Proportion of patients with systemic inflammation and their characteristics for groups at high cardiovascular risk in phase 3 randomized placebo-controlled trials of semaglutide (SELECT, SOUL, FLOW)
28 August 2023
thumbnail
Congress Presentation
Does dulaglutide impact a composite outcome reflecting atherosclerosis? A post-hoc analysis of the REWIND trial
29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources